CSL Limited (ASX:CSL) has announced the successful completion of its $6.3 billion institutional placement with proceeds to support the company's acquisition of Vifor Pharma.
The company said the placement received strong support from existing shareholders and new investors. It was proved at $273 per share, representing an approximately 8.2 per cent discount to its closing price on 13 December.
CSL’s CEO and managing director Paul Perreault said, “We appreciate the support we received from the investment community, including existing and new shareholders, for what is the largest ever primary equity raise in Australia. We are now pleased to launch our share purchase plan for eligible shareholders on Tuesday, 21 December 2021, and we look forward to delivering on the exciting growth opportunities underpinning the acquisition of Vifor Pharma.”
CSL said it will issue approximately 23.1 million new shares under the placement. This represents approximately 5 per cent of the number of CSL shares currently on issue.
The company also announced that shareholders with a registered address in Australia or New Zealand on CSL’s share register at 7:00pm 13 December 2021 that are not in the US will have the opportunity to participate in a non-underwritten share purchase plan. Eligible Shareholders will have the opportunity to apply for up to A$30,000 of new shares without incurring broker or transaction costs.